Electrical Storm Has Worse Prognosis Compared to Sustained Ventricular Tachycardia after VT Ablation.

BACKGROUND

Electrical storm (ES) represents a serious heart rhythm disorder. This study investigates the impact of ES on acute ablation success and long-term outcomes after VT ablation compared to non-ES patients.

METHODS

In this large single-centre study, patients presenting with ES and undergoing VT ablation from June 2018 to April 2021 were compared to patients undergoing VT ablation due to ventricular tachyarrhythmias but without ES. The primary prognostic outcome was VT recurrence, and secondary endpoints were rehospitalization rates and cardiovascular mortality, all after a median follow-up of 22 months.

RESULTS

A total of 311 patients underwent a first VT ablation due to ventricular tachyarrhythmias and were included (63 ± 14 years; 86% male). Of these, 108 presented with ES. In the ES cohort, dilated cardiomyopathy as underlying heart disease was significantly higher ( = 0.008). Major complications were equal across both groups (all > 0.05). Ablation of the clinical VT was achieved in 94% of all patients ( > 0.05). Noninducibility of any VT was achieved in 91% without ES and in 76% with ES ( = 0.001). Patients with ES revealed increased VT recurrence rates during follow-up (65% vs. 40%; log rank = 0.001; HR 1.841, 95% CI 1.289-2.628; = 0.001). Furthermore, ES patients suffered from increased rehospitalization rates (73% vs. 48%; log rank = 0.001; HR 1.948, 95% CI 1.415-2.682; = 0.001) and cardiovascular mortality (18% vs. 9%; log rank = 0.045; HR 1.948, 95% CI 1.004-3.780; = 0.049). After multivariable adjustment, ES was a strong independent predictor of VT recurrence and rehospitalization rates, but not for mortality. In a propensity score-matched cohort, patients with ES still had a higher risk of VT recurrences and rehospitalizations compared to non-ES patients.

CONCLUSIONS

VT ablation in patients with ES is challenging and these patients reveal the highest risk for recurrent VTs, rehospitalization and cardiovascular mortality. These patients need close follow-ups and optimal guideline-directed therapy.